Cargando…

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses

The generation of a vaccine against HIV-1 able to induce durable protective immunity continues a major challenge. The modest efficacy (31.2%) of the phase III RV144 clinical trial provided the first demonstration that a prophylactic HIV/AIDS vaccine is achievable but emphasized the need for further...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perdiguero, Beatriz, Gómez, Carmen Elena, García-Arriaza, Juan, Sánchez-Corzo, Cristina, Sorzano, Carlos Óscar S., Wilmschen, Sarah, von Laer, Dorothee, Asbach, Benedikt, Schmalzl, Christina, Peterhoff, David, Ding, Song, Wagner, Ralf, Kimpel, Janine, Levy, Yves, Pantaleo, Giuseppe, Esteban, Mariano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930178/ https://www.ncbi.nlm.nih.gov/pubmed/31921191 http://dx.doi.org/10.3389/fimmu.2019.02941

Ejemplares similares

Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein
por: Perdiguero, Beatriz, et al.
Publicado: (2023)

A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
por: Kimpel, Janine, et al.
Publicado: (2018)

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

The viral vector vaccine VSV-GP boosts immune response upon repeated applications
por: Tober, R, et al.
Publicado: (2012)

Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways
por: Gómez, Carmen Elena, et al.
Publicado: (2017)

The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer
por: Schreiber, Liesa-Marie, et al.
Publicado: (2019)

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy
por: Dold, Catherine, et al.
Publicado: (2016)

Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer
por: Khasnis, Mukta D., et al.
Publicado: (2016)

Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates
por: Ding, Xiangqing, et al.
Publicado: (2021)

Correction for Kibler et al., “Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC”
por: Kibler, Karen V., et al.
Publicado: (2019)

Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study
por: Perdiguero, Beatriz, et al.
Publicado: (2022)

Improved NYVAC-Based Vaccine Vectors
por: Kibler, Karen V., et al.
Publicado: (2011)

Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques
por: Zurawski, Gerard, et al.
Publicado: (2016)

P19-23. Putative prefusion mechanism of HIV-1 Env revealed by ligand-induced quaternary alterations in o-gp140 trimers
por: Moscoso, CG, et al.
Publicado: (2009)

Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env
por: Heydarchi, Behnaz, et al.
Publicado: (2016)

A recombinant gp145 Env glycoprotein from HIV-1 expressed in two different cell lines: Effects on glycosylation and antigenicity
por: González-Feliciano, José A., et al.
Publicado: (2020)

Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP
por: Vijver, Saskia V., et al.
Publicado: (2023)

Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP
por: Gautam, Saurabh, et al.
Publicado: (2022)

Membrane Fusion Mediated by Baculovirus gp64 Involves Assembly of Stable gp64 Trimers into Multiprotein Aggregates
por: Markovic, Ingrid, et al.
Publicado: (1998)

Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C
por: Perdiguero, Beatriz, et al.
Publicado: (2013)

Antiviral properties of two trimeric recombinant gp41 proteins
por: Delcroix-Genête, Delphine, et al.
Publicado: (2006)

Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens
por: Nájera, José Luis, et al.
Publicado: (2010)

To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity
por: Pinski, Amanda N., et al.
Publicado: (2020)

Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication
por: Dambra, Richard, et al.
Publicado: (2022)

Viral vector delivery of Env trimer immunogens
por: Parks, CL, et al.
Publicado: (2012)

The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1
por: Raman, Suresh C., et al.
Publicado: (2019)

Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike
por: Lee, Jeong Hyun, et al.
Publicado: (2015)

Specific Substitutions in Region V2 of gp120 env confer SHIV Neutralisation Resistance
por: Pisil, Yalcin, et al.
Publicado: (2020)

A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies
por: Sanders, Rogier W., et al.
Publicado: (2013)

Virus-like particles highly expressing DC-SIGN concentrate trimeric HIV-envelope proteins with noncovalently linked immunoreactive gp120 and gp41
por: Vyas, GN
Publicado: (2012)

Antibody to gp41 MPER Alters Functional Properties of HIV-1 Env without Complete Neutralization
por: Kim, Arthur S., et al.
Publicado: (2014)

Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response
por: Heydarchi, Behnaz, et al.
Publicado: (2016)

rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
por: Montefiori, DC, et al.
Publicado: (2012)

Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses
por: Qiu, Xiangguo, et al.
Publicado: (2009)

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
por: Hoff, Nicole A., et al.
Publicado: (2022)

Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies
por: Rusert, Peter, et al.
Publicado: (2011)

Infiltration of dendritic cells and antigen uptake in the muscle after injection of HIV-1 Env gp120 in adjuvant
por: Liang, F, et al.
Publicado: (2012)

Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions
por: Bastian, Arangassery Rosemary, et al.
Publicado: (2013)

The β20–β21 of gp120 is a regulatory switch for HIV-1 Env conformational transitions
por: Herschhorn, Alon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p39nkuq98822pen6dq8mdf30p0